<unk>  is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer.<unk>  can occur anywhere along the gastrointestinal (GI) tract, but oral<unk>  refers to the particular inflammation and ulceration that occurs in the mouth. Oral<unk>  is a common and often debilitating complication of cancer treatment. Oral and gastrointestinal (GI)<unk>  affects almost all patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT), 80% of patients with malignancies of the head and neck receiving radiotherapy, and a wide range of patients receiving chemotherapy. Alimentary tract<unk>  increases mortality and morbidity and contributes to rising health care costs. For most cancer treatment, about 5–15% of patients get<unk> . However, with 5-fluorouracil (5-FU), up to 40% get<unk> , and 10–15% get grade 3–4 oral<unk> . Irinotecan is associated with severe GI<unk>  in over 20% of patients. Seventy-five to eighty percent of bone marrow transplantation recipients experience<unk> , of which oral<unk>  is the most common and most debilitating, especially when melphalan is used. In grade 3 oral<unk> , the patient is unable to eat solid food, and in grade 4, the patient is unable to consume liquids as well. Radiotherapy to the head and neck or to the pelvis or abdomen is associated with Grade 3 and Grade 4 oral or GI<unk> , respectively, often exceeding 50% of patients. Among patients undergoing head and neck radiotherapy, pain and decreased oral function may persist long after the conclusion of therapy. Fractionated radiation dosage increases the risk of<unk>  to > 70% of patients in most trials. Oral<unk>  is particularly profound and prolonged among HSCT recipients who receive total-body irradiation.
Mucositis
Serositis
Myositis
Photosensitivity
Dermatitis
Arthropathy
Leukoedema
Enteropathy